Jack Schalken
Jack Schalken
Hoogleraar experimentele urologie
Verified email at radboudumc.nl
Title
Cited by
Cited by
Year
DD3:: A new prostate-specific gene, highly overexpressed in prostate cancer
MJG Bussemakers, A Van Bokhoven, GW Verhaegh, FP Smit, ...
Cancer research 59 (23), 5975-5979, 1999
13001999
DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer
D Hessels, JMTK Gunnewiek, I van Oort, HFM Karthaus, ...
European urology 44 (1), 8-16, 2003
8262003
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer
R Umbas, JA Schalken, TW Aalders, BS Carter, HFM Karthaus, ...
Cancer research 52 (18), 5104-5109, 1992
7681992
DD3PCA3, a very sensitive and specific marker to detect prostate tumors
JB De Kok, GW Verhaegh, RW Roelofs, D Hessels, LA Kiemeney, ...
Cancer research 62 (9), 2695-2698, 2002
7612002
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
R Umbas, WB Isaacs, PP Bringuier, HE Schaafsma, HFM Karthaus, ...
Cancer research 54 (14), 3929-3933, 1994
6661994
Renal cell carcinoma guideline
B Ljungberg, DC Hanbury, MA Kuczyk, AS Merseburger, PFA Mulders, ...
European urology 51 (6), 1502-1510, 2007
6332007
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
T Rafnar, P Sulem, SN Stacey, F Geller, J Gudmundsson, A Sigurdsson, ...
Nature genetics 41 (2), 221-227, 2009
6152009
Allelic loss of chromosomes 16q and 10q in human prostate cancer.
BS Carter, CM Ewing, WS Ward, BF Treiger, TW Aalders, JA Schalken, ...
Proceedings of the National Academy of Sciences 87 (22), 8751-8755, 1990
5991990
Cadherin switching in human prostate cancer progression
K Tomita, A Van Bokhoven, GJLH van Leenders, ETG Ruijter, CFJ Jansen, ...
Cancer research 60 (13), 3650-3654, 2000
5702000
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy
A Haese, A de la Taille, H Van Poppel, M Marberger, A Stenzl, ...
European urology 54 (5), 1081-1088, 2008
5032008
Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors
PP Bringuier, R Umbas, HE Schaafsma, HFM Karthaus, FMJ Debruyne, ...
Cancer research 53 (14), 3241-3245, 1993
4891993
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
VB Lokeshwar, T Habuchi, HB Grossman, WM Murphy, SH Hautmann, ...
Urology 66 (6), 35-63, 2005
4862005
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer
D Hessels, FP Smit, GW Verhaegh, JA Witjes, EB Cornel, JA Schalken
Clinical Cancer Research 13 (17), 5103-5108, 2007
4182007
Androgen receptors in endocrine‐therapy‐resistant human prostate cancer
TH van der Kwast, J Schalken, JAR de Winter, JCC van Vroonhoven, ...
International journal of cancer 48 (2), 189-193, 1991
4021991
ETS gene fusions in prostate cancer: from discovery to daily clinical practice
SA Tomlins, A Bjartell, AM Chinnaiyan, G Jenster, RK Nam, MA Rubin, ...
European urology 56 (2), 275-286, 2009
3992009
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss
JT Dong, H Suzuki, SS Pin, GS Bova, JA Schalken, WB Isaacs, JC Barrett, ...
Cancer Research 56 (19), 4387-4390, 1996
3851996
Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer
GHJM Leyten, D Hessels, SA Jannink, FP Smit, H de Jong, EB Cornel, ...
European urology 65 (3), 534-542, 2014
3652014
Prevention and early detection of prostate cancer
J Cuzick, MA Thorat, G Andriole, OW Brawley, PH Brown, Z Culig, ...
The lancet oncology 15 (11), e484-e492, 2014
3612014
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
2852015
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming
K Iljin, M Wolf, H Edgren, S Gupta, S Kilpinen, RI Skotheim, M Peltola, ...
Cancer research 66 (21), 10242-10246, 2006
2812006
The system can't perform the operation now. Try again later.
Articles 1–20